BB Biotech AG (BION.SW)
CHF 36.75
(0.68%)
CHF 36.75
(0.68%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -206.6 Million CHF | 42.26% |
| 2022 | -357.81 Million CHF | 11.61% |
| 2021 | -404.8 Million CHF | -158.57% |
| 2020 | 691.17 Million CHF | 2.03% |
| 2019 | 677.43 Million CHF | 243.72% |
| 2018 | -471.34 Million CHF | -168.56% |
| 2017 | 687.5 Million CHF | 185.72% |
| 2016 | -802.06 Million CHF | -222.86% |
| 2015 | 652.81 Million CHF | -55.59% |
| 2014 | 1.47 Billion CHF | 57.77% |
| 2013 | 931.83 Million CHF | 153.33% |
| 2012 | 367.83 Million CHF | 664.7% |
| 2011 | -65.13 Million CHF | 55.49% |
| 2010 | -146.34 Million CHF | -499.57% |
| 2009 | 36.62 Million CHF | -19.24% |
| 2008 | 45.35 Million CHF | 117.09% |
| 2007 | -265.41 Million CHF | -189.25% |
| 2006 | 297.39 Million CHF | -6.48% |
| 2005 | 317.99 Million CHF | 56.84% |
| 2004 | 202.75 Million CHF | 13.06% |
| 2003 | 179.33 Million CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -157.16 Million CHF | -80.48% |
| 2024 Q1 | 260.49 Million CHF | 138.73% |
| 2024 Q2 | -87.08 Million CHF | -133.43% |
| 2023 FY | -206.6 Million CHF | 42.26% |
| 2023 Q4 | 109.11 Million CHF | 325.49% |
| 2023 Q3 | -48.39 Million CHF | -259.03% |
| 2023 Q2 | -13.47 Million CHF | 94.69% |
| 2023 Q1 | -253.85 Million CHF | -621.92% |
| 2022 FY | -357.81 Million CHF | 11.61% |
| 2022 Q4 | -35.16 Million CHF | -116.72% |
| 2022 Q2 | -233.06 Million CHF | 22.28% |
| 2022 Q3 | 210.27 Million CHF | 190.22% |
| 2022 Q1 | -299.86 Million CHF | 45.07% |
| 2021 FY | -404.8 Million CHF | -158.57% |
| 2021 Q1 | 220.94 Million CHF | -66.76% |
| 2021 Q2 | 128.54 Million CHF | -41.82% |
| 2021 Q3 | -208.39 Million CHF | -262.12% |
| 2021 Q4 | -545.9 Million CHF | -161.95% |
| 2020 Q3 | -395.21 Million CHF | -133.5% |
| 2020 FY | 691.17 Million CHF | 2.03% |
| 2020 Q4 | 664.68 Million CHF | 268.18% |
| 2020 Q2 | 1.17 Billion CHF | 255.64% |
| 2020 Q1 | -757.95 Million CHF | -250.02% |
| 2019 Q4 | 505.22 Million CHF | 232.34% |
| 2019 Q2 | -335.8 Million CHF | -137.74% |
| 2019 Q1 | 889.78 Million CHF | 238.41% |
| 2019 FY | 677.43 Million CHF | 243.72% |
| 2019 Q3 | -381.76 Million CHF | -13.69% |
| 2018 Q4 | -642.85 Million CHF | -365.79% |
| 2018 Q2 | -98.58 Million CHF | -449.25% |
| 2018 FY | -471.34 Million CHF | -168.56% |
| 2018 Q1 | 28.22 Million CHF | 118.15% |
| 2018 Q3 | 241.86 Million CHF | 345.34% |
| 2017 Q4 | -155.53 Million CHF | -142.65% |
| 2017 Q3 | 364.64 Million CHF | 252.71% |
| 2017 Q2 | 103.38 Million CHF | -72.43% |
| 2017 FY | 687.5 Million CHF | 185.72% |
| 2017 Q1 | 374.99 Million CHF | 1646.58% |
| 2016 Q4 | -24.24 Million CHF | -106.18% |
| 2016 Q1 | -1.2 Billion CHF | -335.72% |
| 2016 Q3 | 392.11 Million CHF | 1003.06% |
| 2016 FY | -802.06 Million CHF | -222.86% |
| 2016 Q2 | 35.54 Million CHF | 102.95% |
| 2015 Q3 | -575.4 Million CHF | -270.52% |
| 2015 FY | 652.81 Million CHF | -55.59% |
| 2015 Q4 | 511.4 Million CHF | 188.88% |
| 2015 Q2 | 337.44 Million CHF | -11.05% |
| 2015 Q1 | 379.37 Million CHF | -47.76% |
| 2014 Q4 | 726.24 Million CHF | 50.42% |
| 2014 Q3 | 482.81 Million CHF | 147.06% |
| 2014 Q2 | 195.42 Million CHF | 197.68% |
| 2014 FY | 1.47 Billion CHF | 57.77% |
| 2014 Q1 | 65.65 Million CHF | -34.6% |
| 2013 Q2 | 134.09 Million CHF | -62.61% |
| 2013 Q3 | 338.76 Million CHF | 152.64% |
| 2013 Q4 | 100.37 Million CHF | -70.37% |
| 2013 FY | 931.83 Million CHF | 153.33% |
| 2013 Q1 | 358.6 Million CHF | 366.52% |
| 2012 Q2 | 160.33 Million CHF | -17.1% |
| 2012 Q3 | 148.63 Million CHF | -7.3% |
| 2012 Q4 | -134.55 Million CHF | -190.52% |
| 2012 Q1 | 193.41 Million CHF | 78.2% |
| 2012 FY | 367.83 Million CHF | 664.7% |
| 2011 Q3 | -128.98 Million CHF | -53.0% |
| 2011 Q1 | 39.61 Million CHF | -40.8% |
| 2011 FY | -65.13 Million CHF | 55.49% |
| 2011 Q4 | 108.54 Million CHF | 184.15% |
| 2011 Q2 | -84.3 Million CHF | -312.82% |
| 2010 Q3 | 33.54 Million CHF | 111.64% |
| 2010 Q4 | 66.91 Million CHF | 99.48% |
| 2010 Q1 | 41.44 Million CHF | 156.42% |
| 2010 FY | -146.34 Million CHF | -499.57% |
| 2010 Q2 | -288.25 Million CHF | -795.44% |
| 2009 Q2 | 93.29 Million CHF | 201.44% |
| 2009 Q3 | 108.76 Million CHF | 16.58% |
| 2009 Q4 | -73.45 Million CHF | -167.54% |
| 2009 FY | 36.62 Million CHF | -19.24% |
| 2009 Q1 | -91.96 Million CHF | 0.0% |
| 2008 FY | 45.35 Million CHF | 117.09% |
| 2007 FY | -265.41 Million CHF | -189.25% |
| 2006 FY | 297.39 Million CHF | -6.48% |
| 2005 FY | 317.99 Million CHF | 56.84% |
| 2004 FY | 202.75 Million CHF | 13.06% |
| 2003 FY | 179.33 Million CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.55 Million CHF | -1857.205% |
| Basilea Pharmaceutica AG | 10.45 Million CHF | 2076.911% |
| Evolva Holding SA | -105.22 Million CHF | -96.34% |
| Idorsia Ltd | -297.92 Million CHF | 30.65% |
| Kuros Biosciences AG | -13.72 Million CHF | -1405.114% |
| Molecular Partners AG | -61.98 Million CHF | -233.323% |
| Relief Therapeutics Holding AG | -98.18 Million CHF | -110.435% |
| Santhera Pharmaceuticals Holding AG | 54.78 Million CHF | 477.144% |